Kyowa Kirin Pharmaceutical Development, Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.7M
Doctors Paid
11
Transactions
664
2021 Total
$294,561
Payment Breakdown by Category
Research$6.6M (98.2%)
Consulting$120,167 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.6M | 637 | 98.2% |
| Consulting Fee | $120,167 | 27 | 1.8% |
Payments by Type
Research
$6.6M
637 transactions
General
$120,167
27 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo controlled Study of an Anti-OX40 Monoclonal Antibody KHK4083 in Subjects with Moderate to Severe Atopic Dermatitis AD | $1.8M | 0 | 273 |
| A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis (AD) | $1.5M | 1 | 112 |
| Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356 | $717,621 | 0 | 24 |
| Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 mogamulizumab Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma | $652,267 | 0 | 67 |
| Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of 14C-KW-6356 | $629,119 | 0 | 7 |
| Open-Label, Multicenter Phase 1/2 Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors | $433,043 | 0 | 4 |
| Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab KW-0761 in Adult Subjects with Locally Advanced or Metastatic Solid Tumors | $333,272 | 0 | 12 |
| Open-Label, Multicenter Phase 12 Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors | $156,785 | 0 | 21 |
| A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis | $92,179 | 0 | 13 |
| Kyowa Kirin 2455-002 | $83,640 | 0 | 44 |
| KHK2455 | $60,820 | 0 | 2 |
| A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Axial Spondyloarthritis | $60,475 | 0 | 36 |
| An Open-label, Phase 1 Study of KHK2455 in Combination with Avelumab in Adult Subjects with Locally Advanced or Metastatic Urothelial Carcinoma | $35,779 | 0 | 10 |
| Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors | $19,405 | 0 | 2 |
| An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma | $9,865 | 0 | 1 |
| A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mgDay KW-6002 Istradefylline as Monotherapy in Subjects With Parkinsons Disease | $9,761 | 0 | 1 |
| Phase 1 Study of Mogamulizumab KW-0761 in Combination with MEDI4736 and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors | $5,379 | 0 | 2 |
| KW-0761-010 | $4,909 | 0 | 2 |
| Adenosine A2A Blockade With KW-6002 in Parkinsons Disease | $3,225 | 2 | 2 |
| A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody KHK4083 in Subjects with Moderate to Severe Atopic Dermatitis AD | $1,300 | 1 | 2 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Rheumatology | $91,313 | 1 | $91,313 |
| Clinical & Laboratory Dermatological Immunology | $19,369 | 1 | $19,369 |
| Dermatology | $15,250 | 2 | $7,625 |
| Neurology | $9,600 | 4 | $2,400 |
| Legal Medicine | $4,000 | 1 | $4,000 |
| Medical Oncology | $2,999 | 1 | $2,999 |
| Pediatric Dermatology | $1,531 | 1 | $1,531 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Richard Leff, M.d, M.D | Rheumatology | Chadds Ford, PA | $91,313 | $0 |
| April Armstrong, Md, MD | Clinical & Laboratory Dermatological Immunology | Los Angeles, CA | $19,369 | $0 |
| Emma Guttman, Md, MD | Dermatology | New York, NY | $9,750 | $0 |
| Eric Simpson, Md, MD | Dermatology | Portland, OR | $5,500 | $0 |
| Dr. Caroline Tanner, M.d., Ph.d, M.D., PH.D | Legal Medicine | Sunnyvale, CA | $4,000 | $0 |
| Dr. Cheryl Waters, M.d, M.D | Neurology | New York, NY | $3,875 | $0 |
| Steven Horwitz, Md, MD | Medical Oncology | New York, NY | $2,999 | $0 |
| Robert Hauser, Md, MD | Neurology | Tampa, FL | $2,625 | $0 |
| Bonnie Hersh, Md, MD | Neurology | Boston, MA | $1,875 | $0 |
| Lawrence Eichenfield, M.d, M.D | Pediatric Dermatology | San Diego, CA | $1,531 | $0 |
| Mr. John Bertoni, M.d. /Ph.d, M.D. /PH.D | Neurology | Omaha, NE | $1,225 | $0 |
About Kyowa Kirin Pharmaceutical Development, Inc
Kyowa Kirin Pharmaceutical Development, Inc has made $6.7M in payments to 11 healthcare providers, recorded across 664 transactions in the CMS Open Payments database. In 2021, the company paid $294,561. The top product by payment volume is KW-6356 ($1.4M).
Payments were distributed across 7 medical specialties. The top specialty by payment amount is Rheumatology ($91,313 to 1 doctors).
Payment categories include: Consulting ($120,167), Research ($6.6M).
Kyowa Kirin Pharmaceutical Development, Inc is associated with 1 products in the CMS Open Payments database.